You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 1 - 10 of 26411 results
  1. Development of a Blood-based Test for Identifying Synucleinopathy in Patients with Dementia

    SBC: Neurodex Inc            Topic: NINDS

    PROJECT SUMMARY In this Fast Track SBIR application, NeuroDex, Inc. proposes to use its expertise in extracellular vesicle (EV) immunoaffinity isolation to develop a blood test that detects synucleinopathies with high sensitivity, with the long- term goal of helping clinicians identify patients for whom antipsychotic drugs are harmful and contraindicated. Development and commercialization of a sen ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Hybrid ELISA: Simple and specific one-tier assay for Lyme disease

    SBC: KEPHERA DIAGNOSTICS LLC            Topic: NIAID

    Abstract Lyme disease, caused by infection with the spirochete Borrelia burgdorferi or closely related species, is the most common vector-borne disease in the United States, accounting for nearly 500,000 infections per year according to recent public health estimates. It is also one of the few infectious diseases that requires a two-step laboratory testing protocol, comprising a screening assay, t ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Development of a Dual-Targeting ClpP Activating Antibiotic

    SBC: ARIETIS CORPORATION            Topic: NIAID

    The World Health Organization has declared that antimicrobial resistance is one of the biggest threats to global health. It was estimated that by 2050, deaths due to drug resistant bacteria will exceed those caused by cancer. The goal of this project is to develop a new ureadepsipeptide antibiotic (UDEP) to treat infections caused by Gram-positive pathogens, such as bacteremia, pneumonia, endocard ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Eliminating Ventricular Tachycardia: Pivotal Clinical Trial using the Durablate® Catheter

    SBC: Thermedical Inc.            Topic: NHLBI

    Ventricular tachycardia (VT) causes more than half of the 170,000–450,000 sudden cardiac deaths (SCD) that occur annually in the United States. Implantable cardioverter defibrillators (ICDs) are the standard of care, but they are expensive (the total cost of an ICD implant exceeds $50,000) and not curative. Patients who receive ICDs are subject to shocks to halt episodes of VT, and those shocks ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Rapid response to pandemic influenza via multi-antigen RNA-based vaccine

    SBC: TIBA BIOTECH LLC            Topic: NIAID

    Project Abstract Avian influenza A H7N9 causes severe respiratory illness with a high mortality rate, and its zoonotic capacity has raised serious concerns over the possibility of a pandemic. The value of vaccines for pandemic-potential viruses has been demonstrated by the devastating effects of COVID-19 on human health and the economy. Development of H7 Influenza vaccines has lagged, as pandemic ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Biomarker-Based Test of Cure for Chagas Disease

    SBC: KEPHERA DIAGNOSTICS LLC            Topic: NIAID

    Project Summary Chagas disease, caused by infection with Trypanosoma cruzi, is the most prevalent parasitic disease in the western hemisphere, infecting 8-11 million individuals and with over 70 million at risk. The infection is transmitted by an insect vector, but can also be acquired through blood transfusion, organ transplant, or congenitally. Following a brief acute phase, the parasite persist ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Commercialization of an Improved Treatment of Extremity Fractures Using a Regenerative Bone Adhesive to Accelerate Bone Healing in Aging Patients

    SBC: REVBIO, INC.            Topic: NIA

    Project Abstract/Summary In the U.S., about 2.1 million people experience a fragility fracture each year. This number is expected to double or triple by 2040 as the population ages. Injuries in the upper and lower extremities equate to more than 40% of fragility fractures, and experiencing a prior fracture is associated with an 86% increased risk of recurrence. Falls from standing height and other ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Proposal for IRIS Software Suite

    SBC: OUTERLINK CORP            Topic: AF203DCSO1

    The Outerlink IRIS system is a commercially successful, real-time flight data processing system that includes a satellite-based data link. The system records voice, video, and aircraft flight data while at the same time Interrogating the data for informat

    SBIR Phase II 2023 Department of DefenseAir Force
  9. Diagnostic tool for assessment and tracking of microbial load in bloodstream infections

    SBC: HELIXBIND, INC.            Topic: NIAID

    PROJECT SUMMARY Leading to over 270,000 deaths in the US annually, septicemia is the systemic inflammatory response to a bloodstream infection (BSI). Early diagnosis and treatment of BSIs have demonstrated improved patient outcomes and reduced hospitalization time. However, currently accepted diagnostic approaches require a blood culturing step, which is not only slow, but also demonstrates reduce ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Commercialization Readiness Pilot (CRP) program support for: Direct-from-specimen identification of pathogens common in endocarditis

    SBC: HELIXBIND, INC.            Topic: NIAID

    PROJECT SUMMARY Infective Endocarditis (IE) occurs when bacteria or fungi adhere to the endocardial surface forming small lesions. This invasive disease is characterized by a mortality rate exceeding 25%, is associated with extended hospitalization, and often impairs the quality of life for those who survive. Early microbial diagnosis and antimicrobial intervention are crucial to improved patient ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government